Research Analysts’ Weekly Ratings Changes for Evaxion A/S (EVAX)

Several brokerages have updated their recommendations and price targets on shares of Evaxion A/S (NASDAQ: EVAX) in the last few weeks:

• 3/10/2026 – Evaxion A/S is now covered by JonesTrading. They set a “buy” rating and a $10.00 price target on the stock.
• 3/9/2026 – Evaxion A/S had its price target lowered by Lake Street Capital from $11.00 to $9.00. They now have a “buy” rating on the stock.
• 3/9/2026 – Evaxion A/S had its “buy” rating reaffirmed by HC Wainwright. They now have a $16.00 price target on the stock.
• 2/19/2026 – Evaxion A/S is now covered by Maxim Group. They set a “buy” rating and a $10.00 price target on the stock.

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.